Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity
Niels Heemskerk, Mandy Gruijs, A. Robin Temming, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 6
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Céline M. Laumont, Allyson C. Banville, Mara Gilardi, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 7, pp. 414-430
Open Access | Times Cited: 286
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 110
New immune cell engagers for cancer immunotherapy
Aurore Fenis, Olivier Demaria, Laurent Gauthier, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 7, pp. 471-486
Closed Access | Times Cited: 54
Neutrophils bearing adhesive polymer micropatches as a drug-free cancer immunotherapy
Ninad Kumbhojkar, Supriya Prakash, Tatsuya Fukuta, et al.
Nature Biomedical Engineering (2024) Vol. 8, Iss. 5, pp. 579-592
Closed Access | Times Cited: 28
N1 versus N2 and PMN‐MDSC: A critical appraisal of current concepts on tumor‐associated neutrophils and new directions for human oncology
Benedict Boateng Antuamwine, Rebeka Bosnjakovic, Francisca Hofmann‐Vega, et al.
Immunological Reviews (2022) Vol. 314, Iss. 1, pp. 250-279
Open Access | Times Cited: 45
The present and future of immunocytokines for cancer treatment
Dennis Y. Gout, Lotte S. Groen, Marjolein van Egmond
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 10
Open Access | Times Cited: 40
The evolution and heterogeneity of neutrophils in cancers: origins, subsets, functions, orchestrations and clinical applications
Siyao Liu, Wenchuan Wu, Yueshan Du, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 28
Therapeutic Monoclonal Antibodies against Cancer: Present and Future
Marisa Delgado, José A. García‐Sanz
Cells (2023) Vol. 12, Iss. 24, pp. 2837-2837
Open Access | Times Cited: 27
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
Kohei Okuyama, Tomofumi Naruse, Souichi Yanamoto
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 21
Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases
Camille Rolin, Jacques Zimmer, Carole Seguin‐Devaux
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 7, pp. 643-661
Open Access | Times Cited: 10
Neutrophils as immune effector cells in antibody therapy in cancer
Leonie M. Behrens, Marjolein van Egmond, Timo K. van den Berg
Immunological Reviews (2022) Vol. 314, Iss. 1, pp. 280-301
Open Access | Times Cited: 28
Cancer immunotherapies: A hope for the uncurable?
Firas Hamdan, Vincenzo Cerullo
Frontiers in Molecular Medicine (2023) Vol. 3
Open Access | Times Cited: 17
Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment
Justyn Fine, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Annual Review of Chemical and Biomolecular Engineering (2024) Vol. 15, Iss. 1, pp. 105-138
Closed Access | Times Cited: 5
Adaptations of neutrophils in cancer
Melissa Ng, Daniela Cerezo‐Wallis, Lai Guan Ng, et al.
Immunity (2025) Vol. 58, Iss. 1, pp. 40-58
Closed Access
From ulcerative colitis to metastatic colorectal cancer: The neutrophil contribution
Iliana I. León-Vega, Reyna Oregon, Michael Schnoor, et al.
American Journal Of Pathology (2025)
Closed Access
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
Xiaohan Guo, Yi Wu, Ying Xue, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Therapeutic exploitation of neutrophils to fight cancer
Mandy Gruijs, Celine Angeli Natascha Sewnath, Marjolein van Egmond
Seminars in Immunology (2021) Vol. 57, pp. 101581-101581
Open Access | Times Cited: 27
Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab
Federico Innocenti, Akram Yazdani, Naim U. Rashid, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 8, pp. 1690-1700
Open Access | Times Cited: 16
Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA
Andréa Cottignies-Calamarte, Daniela Tudor, Morgane Bomsel
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
IgA2 immune complexes selectively promote inflammation by human CD103+ dendritic cells
Lynn Mes, Ulrike Steffen, Hung‐Jen Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model
M. Chernyavska, Charlotte K.J.C. Hermans, Chilam Chan, et al.
Organs-on-a-Chip (2022) Vol. 4, pp. 100019-100019
Open Access | Times Cited: 11
Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer
Celine Angeli Natascha Sewnath, Leonie M. Behrens, Marjolein van Egmond
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 8, pp. 983-995
Open Access | Times Cited: 11
Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody
Huixia He, Feifei Lei, Le Huang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114797-114797
Open Access | Times Cited: 6
Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains
Marjolein C. Stip, J.H. Marco Jansen, Maaike Nederend, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 9, pp. 3063-3077
Open Access | Times Cited: 5
Anti-FcαRI Monoclonal Antibodies Resolve IgA Autoantibody-Mediated Disease
Amélie Bos, Esil Aleyd, Lydia P. E. van der Steen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top